Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 39Terminated 14Unknown 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 116Carcinoma, Non-Small-Cell Lung 67Multiple Myeloma 56Prostatic Neoplasms 55Lymphoma 40Neoplasm Metastasis 38Leukemia, Lymphocytic, Chronic, B-Cell 35Melanoma 32Leukemia, Myeloid, Acute 32Neoplasms 31Ovarian Neoplasms 30Lymphoma, Non-Hodgkin 27Lung Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Glioblastoma 22Myelodysplastic Syndromes 20Fallopian Tube Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Hodgkin Disease 19Sarcoma 18Carcinoma, Renal Cell 18Squamous Cell Carcinoma of Head and Neck 16Small Cell Lung Carcinoma 16Glioma 16Urinary Bladder Neoplasms 15Colorectal Neoplasms 15Lymphoma, Mantle-Cell 14Leukemia 14Head and Neck Neoplasms 14

Interventions

Gemtuzumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Leukemia, Erythroblastic, Acute × Clear all
NCT00658814 2026-05-29

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡